首页
小分子和化合物库
按“信号通路”分类
免疫学/炎症
CTLA-4
Tremelimumab (anti-CTLA-4), 细胞毒性 T 淋巴细胞相关蛋白 4 (CD152) 抗体

Tremelimumab (anti-CTLA-4), 细胞毒性 T 淋巴细胞相关蛋白 4 (CD152) 抗体

级别和纯度:

≥95%(SDS-PAGE&SEC-HPLC)
见COA

应用:

Animal Model
ELISA
Flow Cytometry
Functional Assay

宿主种属: 人(Human)
种属反应性: 人(Human), 食蟹猴(Cynomolgus monkey)
亚型: Human IgG2
偶联: Unconjugated

有货

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭

货号 (SKU)	包装规格	是否现货
Ab169301-100μg	100μg	现货
Ab169301-1mg	1mg	现货
Ab169301-5mg	5mg	现货
Ab169301-10mg	10mg	期货

查看相关系列

点击查看靶蛋白信息: CTLA4

Accession#:P16410 (8) CTLA4 (11) cytotoxic T-lymphocyte-associated protein 4 (CD152) Antibody (2) Gene ID:1493 (9)

Skip to the end of the images gallery

Skip to the beginning of the images gallery

基本信息

产品名称	Tremelimumab (anti-CTLA-4), 细胞毒性 T 淋巴细胞相关蛋白 4 (CD152) 抗体
别名	曲美木单抗 \| 特瑞莫单抗（抗CTLA-4）
英文别名	Tremelimumab \| Ticilimumab \| CP-675 \| 206 \| ALPS5 antibody \| CD 152 antibody \| CD antibody \| CD152 antibody \| CD152 antigen antibody \| CD152 isoform antibody \| Celiac disease 3 antibody \| CELIAC3 antibody \| CTLA 4 antibody \| CTLA-4 antibody \| CTLA4 antibo
规格或纯度	无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA
宿主种属	人(Human)
特异性	CTLA-4 / CD152
应用	ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR)
种属反应性	人(Human),食蟹猴(Cynomolgus monkey)
偶联	Unconjugated
作用类型	抑制剂
作用机制	细胞毒性 T 淋巴细胞相关蛋白 4 (CD152) 抗体

产品属性

克隆类型	重组抗体
Format	Whole IgG
亚型	Human IgG2
轻链亚型	kappa
SDS-PAGE	26.1 kDa (Light Chain) & 52.2 kDa (Heavy Chain), under reducing conditions; 178.0 kDa, under non-reducing conditions.
纯化方法	Protein A purified
纯度	>95%
来源	CHO supernatant
物理外观	Liquid
储存缓冲液	Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂	No
浓度	见COA
储存温度	-80℃储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。
CAS编号和信息	745013-59-6
分子类型	抗体

关联靶点（人）

CTLA4 Tclin 细胞毒性T淋巴细胞蛋白4(Cytotoxic T-lymphocyte protein 4) (0 活性数据)

点击查看靶蛋白信息： CTLA4

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

作用机制

作用机制	Action Type	target ID	Target Name	Target Type	Target Organism	Binding Site Name	参考文献

图片

ELISA: Tremelimumab (anti-CTLA-4) (Ab169301)

Tremelimumab (anti-CTLA-4) (Ab169301) - ELISA
Immobilized Recombinant Human CTLA-4 Protein at 2 μg/mL can bind Tremelimumab (anti-CTLA-4) (Ab169301) with the EC₅₀ of 4.38 ng/mL.

SEC: Tremelimumab (anti-CTLA-4) (Ab169301)

Tremelimumab (anti-CTLA-4) (Ab169301) - SEC
The purity of Tremelimumab (anti-CTLA-4) (Ab169301) is more than 95% verified by HPLC.

质检证书（CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):

输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！

找到5个结果

批号(Lot Number)	证书类型	货号
ZJ23F1001509	分析证书	Ab169301
ZJ23F1001510	分析证书	Ab169301
ZJ24F1012680	分析证书	Ab169301
ZJ24F1012769	分析证书	Ab169301
ZJ24F1012770	分析证书	Ab169301

可替换产品

引用文献

1. Reuben JM, Lee BN, Li C, Gomez-Navarro J, Bozon VA, Parker CA, Hernandez IM, Gutierrez C, Lopez-Berestein G, Camacho LH. (2006) Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma.. Cancer, 106 (11): (2437-44). [PMID:16615096]
2. Calabrò L, Morra A, Fonsatti E, Cutaia O, Fazio C, Annesi D, Lenoci M, Amato G, Danielli R, Altomonte M et al.. (2015) Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.. Lancet Respir Med, 3 (4): (301-9). [PMID:25819643]
3. Joshua AM, Monzon JG, Mihalcioiu C, Hogg D, Smylie M, Cheng T. (2015) A phase 2 study of tremelimumab in patients with advanced uveal melanoma.. Melanoma Res, 25 (4): (342-7). [PMID:26050146]
4. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. (1991) CTLA-4 is a second receptor for the B cell activation antigen B7.. J Exp Med, 174 (3): (561-9). [PMID:1714933]
5. Harper, K K and 5 more authors.. (1991) CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location.. Journal of immunology (Baltimore, Md. : 1950), (1): [PMID:1713603]
6. Dariavach, P P, Mattéi, M G MG, Golstein, P P and Lefranc, M P MP.. (1988) Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains.. European journal of immunology, [PMID:3220103]
7. Metzler, W J WJ and 10 more authors.. (1997) Solution structure of human CTLA-4 and delineation of a CD80/CD86 binding site conserved in CD28.. Nature structural biology, [PMID:9228944]
8. Marron, M P MP and 20 more authors.. (1997) Insulin-dependent diabetes mellitus (IDDM) is associated with CTLA4 polymorphisms in multiple ethnic groups.. Human molecular genetics, [PMID:9259273]
9. Schneider, H H, Schwartzberg, P L PL and Rudd, C E CE.. (1998) Resting lymphocyte kinase (Rlk/Txk) phosphorylates the YVKM motif and regulates PI 3-kinase binding to T-cell antigen CTLA-4.. Biochemical and biophysical research communications, (9): [PMID:9813138]
10. Djilali-Saiah, I I and 5 more authors.. (1998) CTLA-4 gene polymorphism is associated with predisposition to coeliac disease.. Gut, [PMID:10189842]
11. Vaidya, B B and 6 more authors.. (1999) Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphism confers susceptibility to thyroid associated orbitopathy.. Lancet (London, England), (28): [PMID:10475192]
12. Ling, V V and 5 more authors.. (1999) Complete sequence determination of the mouse and human CTLA4 gene loci: cross-species DNA sequence similarity beyond exon borders.. Genomics, (15): [PMID:10493833]
13. Chikuma, S S, Murakami, M M, Tanaka, K K and Uede, T T.. (2000) Janus kinase 2 is associated with a box 1-like motif and phosphorylates a critical tyrosine residue in the cytoplasmic region of cytotoxic T lymphocyte associated molecule-4.. Journal of cellular biochemistry, [PMID:10842319]
14. Deng, Z Z and 11 more authors.. (2000) Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene.. American journal of human genetics, [PMID:10903931]
15. Chistyakov, D A DA and 7 more authors.. (2000) Complex association analysis of graves disease using a set of polymorphic markers.. Molecular genetics and metabolism, [PMID:10924276]
16. Schwartz, J C JC, Zhang, X X, Fedorov, A A AA, Nathenson, S G SG and Almo, S C SC.. (2001) Structural basis for co-stimulation by the human CTLA-4/B7-2 complex.. Nature, (29): [PMID:11279501]
17. Stamper, C C CC and 9 more authors.. (2001) Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses.. Nature, (29): [PMID:11279502]
18. Ling, V V and 9 more authors.. (2001) Assembly and annotation of human chromosome 2q33 sequence containing the CD28, CTLA4, and ICOS gene cluster: analysis by computational, comparative, and microarray approaches.. Genomics, [PMID:11735222]
19. Ueda, Hironori H and 52 more authors.. (2003) Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease.. Nature, (29): [PMID:12724780]
20. Barreto, Marta M and 12 more authors.. (2004) Evidence for CTLA4 as a susceptibility gene for systemic lupus erythematosus.. European journal of human genetics : EJHG, [PMID:15138458]
21. Thio, Chloe L CL and 8 more authors.. (2004) Cytotoxic T-lymphocyte antigen 4 gene and recovery from hepatitis B virus infection.. Journal of virology, [PMID:15452244]
22. Hunt, Karen A KA and 8 more authors.. (2005) A common CTLA4 haplotype associated with coeliac disease.. European journal of human genetics : EJHG, [PMID:15657618]
23. Lee, Young Ho YH, Harley, John B JB and Nath, Swapan K SK.. (2005) CTLA-4 polymorphisms and systemic lupus erythematosus (SLE): a meta-analysis.. Human genetics, [PMID:15688186]
24. Darlington, Peter J PJ, Kirchhof, Mark G MG, Criado, Gabriel G, Sondhi, Jitin J and Madrenas, Joaquín J.. (2005) Hierarchical regulation of CTLA-4 dimer-based lattice formation and its biological relevance for T cell inactivation.. Journal of immunology (Baltimore, Md. : 1950), (15): [PMID:16002699]
25. Ribas, Antoni A and 8 more authors.. (2007) Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer.. The oncologist, [PMID:17673618]
26. Yang, James C JC and 12 more authors.. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis.. Journal of immunotherapy (Hagerstown, Md. : 1997), [PMID:18049334]
27. Valk, Elke; Rudd, Christopher E and Schneider, Helga.. (2008) CTLA-4 trafficking and surface expression.. Trends in immunology, [PMID:18468488]
28. Gu, Ming M and 6 more authors.. (2008) Identification of CTLA-4 isoforms produced by alternative splicing and their association with myasthenia gravis.. Clinical immunology (Orlando, Fla.), [PMID:18595775]
29. Linsley, Peter S PS and Nadler, Steven G SG.. (2009) The clinical utility of inhibiting CD28-mediated costimulation.. Immunological reviews, [PMID:19426230]
30. Yu, Chao and 11 more authors.. (2011) Rigid-body ligand recognition drives cytotoxic T-lymphocyte antigen 4 (CTLA-4) receptor triggering.. The Journal of biological chemistry, (25): [PMID:21156796]
31. Kuehn, Hye Sun HS and 35 more authors.. (2014) Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4.. Science (New York, N.Y.), (26): [PMID:25213377]
32. Schubert, Desirée D and 39 more authors.. (2014) Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations.. Nature medicine, [PMID:25329329]

溶液计算器

摩尔浓度计算器

计算溶液所需的质量、体积或浓度。

质量

浓度

体积

分子量

g/mol

稀释计算器

计算配制储备溶液所需的稀释度。

浓度1（C1）

体积 1 (V1)

浓度 2 (C2)

体积 2 (V2)

复溶计算器

复溶计算器允许您快速计算试剂的体积，以复溶小瓶。只需输入试剂的质量和目标浓度，计算器将确定其余部分。

体积（添加到小瓶中）

质量（小瓶）

所需的复溶浓度

Tremelimumab (anti-CTLA-4), 细胞毒性 T 淋巴细胞相关蛋白 4 (CD152) 抗体

库存信息

库存信息

库存信息

库存信息

基本信息

产品属性

关联靶点（人）

作用机制

图片

质检证书（CoA,COO,BSE/TSE 和分析图谱)

相关产品

可替换产品

引用文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器